Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Individualized Treatment for Advanced Pancreatic Cancer
NCT00276744Phase 2Terminated
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Oct 2005
- Primary completion
- Apr 2010
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib, capecitabine, cetuximab, docetaxel, erlotinib in pancreatic cancer (PC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Oct 2005; status: terminated.
02
Drugs
bortezomibcapecitabinecetuximabdocetaxelerlotinib
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT00276744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00276744.